共 50 条
- [1] Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer[J]. CANCER RESEARCH, 2011, 71Singh, J. C.Stein, S.Volm, M.Smith, J.Novik, Y.Speyer, J.Adams, S.Meyers, M.Muggia, F.Schneider, R.Formenti, S.Omene, C.Choi, H.Davis, S.Goldberg, J.Tiersten, A.
- [2] Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)Singh, Jasmeet ChadhaVolm, MatthewNovik, YelenaSpeyer, James L.Adams, SylviaOmene, Coral OghenerukevweMeyers, Marleen IvaSmith, Julia AnneSchneider, RobertFormenti, SilviaGoldberg, Judith D.Li, XiaochunDavis, SamanthaBeardslee, BrianTiersten, Amy
- [3] RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Singh, Jasmeet ChadhaStein, StacyVolm, MatthewSmith, Julia AnneAdams, SylviaMeyers, MarleneSpeyer, James L.Novik, YelenaSchneider, RobertFormenti, SylviaMuggia, FrancoJhaveri, Komal L.Goldberg, Judith D.Heese, ScottLi, XiaochunDavis, SamanthaTiersten, Amy
- [4] Phase I trial with carboplatin and RAD001 in metastatic breast cancer[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Eucker, J.Schwarzlose-Schwarck, S.Martus, P.Regierer, A. C.Schulz, C. O.Liu, H.Scholz, C. W.Schefe, J. H.Possinger, K.
- [5] A Phase 2 trial of RAD 001 and Carboplatin in patients with triple negative metastatic breast cancer[J]. CANCER RESEARCH, 2012, 72Singh, J. C.Volm, M.Novik, Y.Speyer, J.Adams, S.Omene, C. O.Meyers, M.Smith, J. A.Schneider, R.Formenti, S.Goldberg, J. D.Li, X.Davis, S.Beardslee, B.Tiersten, A.
- [6] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer[J]. CANCER RESEARCH, 2022, 82 (04)Garrido-Castro, Ana C.Graham, NoahBi, KevinPark, JihyeFu, JingxinKeenan, TanyaRichardson, Edward ThomasPastorello, RicardoLange, PaulinaAttaya, VictoriaWesolowski, RobertSinclair, NatalieLucas, ZarahLo, SteveTung, NadineFaggen, MeredithKaufman, Peter A.Block, Caroline C.Briccetti, FredToke, MadhaviChen, WendyWucherpfennig, KaiMarx, SaschaAgudo, JudithGuerriero, Jennifer L.Schnitt, StuartLin, Nancy U.Winer, Eric P.Mittendorf, Elizabeth A.Tayob, NabihahVan Allen, EliezerTolaney, Sara M.
- [7] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)Singh, J. C.Stein, S.Volm, M.Smith, J. A.Novik, Y.Speyer, J. L.Adams, S.Meyers, M. I.Muggia, F.Schneider, R.Formenti, S.Davis, S.Choi, H.Tiersten, A.
- [8] Neoadjuvant phase II trial with eribulin and carboplatin in patients with triple-negative breast cancer[J]. MOLECULAR CANCER RESEARCH, 2013, 11Giordano, Sara BarnatoRao, ShreyasHamdan, RandalaJeruss, JacquelineBethke, KevinHansen, NoraKhan, SeemaVon Roenn, JamieRosen, StevenGradishar, William J.Siziopikou, KalliopiMeservey, CaitlinKaklamani, Virginia
- [9] Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer[J]. ONCOLOGIST, 2023, 28 (07): : E498 - E507Yuan, YuanYost, Susan E.Cui, YujieRuel, ChristopherMurga, MireyaTang, AileenMartinez, NormaSchmolze, DanielWaisman, JamesPatel, NikiVora, LalitTumyan, LusineBozoghlanian, MariStewart, DaphneFrankel, Paul H.
- [10] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)[J]. CANCER RESEARCH, 2017, 77Obeid, E.Miller, K. D.Sparano, J. A.Blackwell, K.Goldstein, L. J.